We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01855360
Recruitment Status : Completed
First Posted : May 16, 2013
Last Update Posted : June 20, 2017
Information provided by (Responsible Party):
Rodney H. Falk, MD, Brigham and Women's Hospital

March 12, 2013
May 16, 2013
June 20, 2017
June 2013
May 31, 2015   (Final data collection date for primary outcome measure)
The rate of progression of transthyretin cardiac amyloidosis, as measured by changes in strain echocardiography, in a group of patients taking a combination of doxycycline and TUDCA. [ Time Frame: Time Frame: * (FDAAA) outcome measure is assessed every 6 months by serial echocardiography, with final measurement 18 months after enrollment. ]
Outcome measure, namely changes in longitudinal echocardiographic strain, will be compared to previously determined changes derived from a cohort of patients with TTR cardiac amyloidosis who were not receiving specific therapy for amyloid deposition.
Same as current
Complete list of historical versions of study NCT01855360 on ClinicalTrials.gov Archive Site
  • Number of patients with adverse events to the medications over the period of therapy (18 months) [ Time Frame: 18 months ]
    Measurements of kidney function (BUN and creatinine) and blood counts will be done every 3 months.
  • To evaluate general and health related quality of life (QoL) in SSA and ATTR subjects. [ Time Frame: Measurements made every 6 months for 18 months. ]
Same as current
Not Provided
Not Provided
Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy.
The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.
Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Amyloidosis; Heart (Manifestation)
  • Senile Cardiac Amyloidosis
Drug: Tauroursodeoxycholic Acid and Doxycycline
Experimental: TUDCA and Doxycycline
TUDCA taken orally, 250 mg three times daily. Doxycycline taken orally, 100 mg twice daily
Intervention: Drug: Tauroursodeoxycholic Acid and Doxycycline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 31, 2015
May 31, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented transthyretin cardiac amyloidosis by biopsy and staining using immunohistochemistry or mass spectrometry
  • Echocardiographic appearance of left ventricular wall thickness of 13mm or more in the absence of hypertensive heart disease
  • Confirmed ATTR or SSA by genetic testing
  • Age 18-90
  • Male or non-pregnant, non-lactating females
  • Willingness to return to the treatment center for follow-up

Exclusion Criteria:

  • Prior liver transplantation or liver transplantation anticipated in less than 6 months
  • Alanine Transaminase and/or Aspartate Transaminase ≥2 x upper normal limit (UNL)
  • Alkaline Phosphatase ≥2 x UNL
  • Creatinine clearance <20 mL/min
  • Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study
  • History of poor compliance
  • History of hypersensitivity to any of the ingredients of the study therapies
  • Any investigational drug within 4 weeks prior to study entry or during the study
  • Current use of diflunisal for therapy of amyloidosis
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Rodney H. Falk, MD, Brigham and Women's Hospital
Brigham and Women's Hospital
Not Provided
Principal Investigator: Rodney H Falk, MD Brigham and Women's Hospital, Boston MA
Brigham and Women's Hospital
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP